These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
4. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Muenter MD Neurology; 1970 Dec; 20(12):6-13. PubMed ID: 4924343 [No Abstract] [Full Text] [Related]
5. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744 [No Abstract] [Full Text] [Related]
6. The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary. Keenan RE Neurology; 1970 Dec; 20(12):46-59. PubMed ID: 5531294 [No Abstract] [Full Text] [Related]
7. MK 486 and levodopa in treatment of Parkinsonism. Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885 [No Abstract] [Full Text] [Related]
9. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085 [No Abstract] [Full Text] [Related]
10. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586 [No Abstract] [Full Text] [Related]
11. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism]. Sato G; Ito H; Handa Y; Takahashi I; Iijima K No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821 [No Abstract] [Full Text] [Related]
12. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342 [No Abstract] [Full Text] [Related]
13. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ; Somerville B Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
14. [Clinical study of L-dopa in Parkinson's disease]. Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350 [No Abstract] [Full Text] [Related]
15. [Long-term treatment of Parkinsonism with L-dopa]. Presthus J; Holmsen R Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916 [No Abstract] [Full Text] [Related]
16. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism]. Gerstenbrand F; Grünberger J; Schubert H Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895 [No Abstract] [Full Text] [Related]
17. [Clinical experience with L-DOPA in the treatment of parkinsonism]. Chiba T No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833 [No Abstract] [Full Text] [Related]
18. [Use of L-DOPA in the therapy of parkinsonism]. D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734 [No Abstract] [Full Text] [Related]
19. Metabolism and clinical assessment of L-dopa in parkinsonism. Ericsson AD; McCann D; Sharpless N; Reveno W Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027 [No Abstract] [Full Text] [Related]